An FDA panel has overwhelmingly voted to recommend approval of the Cartiva Inc.'s Cartiva synthetic cartilage toe implant despite strong reservations that the firm's data is relatively weak.
On April 20, the FDA's Orthopaedic and Rehabilitation Devices Panel voted 8-2 with two abstentions that the benefits of the implant outweigh the risks. The device, made from an organic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?